Literature DB >> 11180109

Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered.

M F Bachmann1, A Gallimore, E Jones, B Ecabert, H Acha-Orbea, M Kopf.   

Abstract

CTLA-4 is a critical negative regulator of T cell responses and CTLA-4-deficient (CTLA-4(-/-)) mice die of a lymphproliferative disease. Nevertheless, RAG-2-deficient mice reconstituted with a mixture of CTLA-4(-/-) and normal (CTLA-4(+/+)) bone marrow survive in the absence of any signs of disease, although 50% of their T cells do not express CTLA-4. Using such mixed chimeras, we analyzed the role of CTLA-4 in specific T cell responses to lymphocytic choriomeningitis virus, Leishmania major and mouse mammary tumor virus, which cause acute, chronic and persistent infections, respectively. The populations of antigen-specific CTLA-4(-/-)CD4(+) and CTLA-4(-/-)CD8(+) T cells became activated, expanded and contracted indistinguishably from CTLA-4(+/+)CD4(+) and CTLA-4(+/+)CD8(+) T cells after infection with all three pathogens. Thus, CTLA-4 is not involved in the down-regulation of specific T cell responses and peripheral deletion in a T cell-autonomous fashion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11180109     DOI: 10.1002/1521-4141(200102)31:2<450::aid-immu450>3.0.co;2-x

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  24 in total

Review 1.  Reflections on CD8 T-cell activation and memory.

Authors:  David Masopust; Rafi Ahmed
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  VSIG4, a B7 family-related protein, is a negative regulator of T cell activation.

Authors:  Lorenz Vogt; Nicole Schmitz; Michael O Kurrer; Monika Bauer; Heather I Hinton; Silvia Behnke; Dominique Gatto; Peter Sebbel; Roger R Beerli; Ivo Sonderegger; Manfred Kopf; Philippe Saudan; Martin F Bachmann
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

3.  A VISTA on PD-1H.

Authors:  Yang Liu
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

4.  Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell.

Authors:  James E D Thaventhiran; Anja Hoffmann; Lukasz Magiera; Maike de la Roche; Holger Lingel; Monika Brunner-Weinzierl; Douglas T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-27       Impact factor: 11.205

5.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Nat Rev Immunol       Date:  2011-11-25       Impact factor: 53.106

6.  CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.

Authors:  Luca Gattinoni; Anju Ranganathan; Deborah R Surman; Douglas C Palmer; Paul A Antony; Marc R Theoret; David M Heimann; Steven A Rosenberg; Nicholas P Restifo
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

Review 7.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

8.  Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity.

Authors:  Dirk Homann; Wolfgang Dummer; Tom Wolfe; Evelyn Rodrigo; Argyrios N Theofilopoulos; Michael B A Oldstone; Matthias G von Herrath
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

9.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.

Authors:  Josef Kurtz; Forum Raval; Casey Vallot; Jayden Der; Megan Sykes
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

10.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

Authors:  Karl S Peggs; Sergio A Quezada; Cynthia A Chambers; Alan J Korman; James P Allison
Journal:  J Exp Med       Date:  2009-07-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.